Clinical Trials Logo

Hand, Foot and Mouth Disease clinical trials

View clinical trials related to Hand, Foot and Mouth Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06251219 Not yet recruiting - Clinical trials for Hand, Foot and Mouth Disease

Active Case Finding of Clinical Hand Foot Mouth Disease in Children Aged 6 Months Old to 18 Years Old in Indonesia

Start date: February 1, 2024
Phase:
Study type: Observational

An observational study of active case surveillance to identify the pathogens of clinically diagnosed HFMD cases aged 6 months to 18 years old recruited from puskesmas and hospitals in Indonesia.

NCT ID: NCT05397587 Not yet recruiting - Clinical trials for Hand, Foot and Mouth Disease

An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)

Start date: July 30, 2022
Phase: Phase 4
Study type: Interventional

This is an open,observational and follow-up clinical trial based on the clinical trial of EV71 vaccine extended age group.The purpose of this study is to evaluate the immunity persistence of EV71 vaccine developed by Sinovac Biotech Co., Ltd in subjects aged 6 ~71 months after full immunization of two doses of vaccine.

NCT ID: NCT04637919 Not yet recruiting - Clinical trials for Hand, Foot and Mouth Disease

Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects

Start date: December 2020
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and immunogenicity of high-dose IN-B001 after administration in healthy subjects

NCT ID: NCT02889497 Not yet recruiting - Clinical trials for Hand Foot and Mouth Disease

Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months

Start date: September 2016
Phase: Phase 4
Study type: Interventional

This study evaluates the safety,three batches consistency and immunity duration of the post-marketing inactivated Enterovirus Type 71 (EV71) vaccine in children aged 6-71 months.This study has two groups:safety observation group and immunogenicity observation group.20000 subjects will receive 2 doses vaccines and be observed for safety among 2 epidemic cycles of HFMD.In the immunogenicity observation group, 900 subjects will be randomly received 3 batches vaccines(2 doses),and blood sampled at days 0 and 56.